Skip to main content

Peer Review reports

From: A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

Original Submission
15 Jan 2016 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
11 Aug 2016 Editorially accepted
17 Aug 2016 Article published 10.1186/s12885-016-2709-z

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us